The American Journal of Medicine
Volume 121, Issue 1 , Pages 43-49 , January 2008

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis

  • Jeffrey S. Berger, MD, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • Jeffrey Berger is funded by an American Heart Association Fellow to Faculty Award 0775074N.
    • Corresponding Author InformationRequests for reprints should be addressed to Jeffrey S. Berger, MD, MS, Duke Clinical Research Institute, Duke University Medical Center, Department of Internal Medicine, DUMC 31007, Durham, NC 27710.
    • ,
  • David L. Brown, MD

      Affiliations

    • Stony Brook University School of Medicine, Stony Brook, NY.
    • ,
  • Richard C. Becker, MD

      Affiliations

    • Duke Clinical Research Institute, Durham, NC

References 

  1. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol. 1991;68:28B–35B
  2. Fuster V, Stein B, Ambrose JA, et al. Atherosclerotic plaque rupture and thrombosis (Evolving concepts). Circulation. 1990;82(3 Suppl):II47–II59
  3. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–3384
  4. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs. 2005;5:399–408
  5. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003;23:2131–2137
  6. Anonymous Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (Antiplatelet Trialists’ Collaboration). [see comment] [erratum appears in BMJ. 1994;308:1540] BMJ. 1994;308:81–106
  7. Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. [see comment] [erratum appears in BMJ. 2002;324:141] BMJ. 2002;324:71–86
  8. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug Discov. 2003;2:775–789
  9. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents (The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology). Eur Heart J. 2004;25:166–181
  10. Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol. 1989;14:813–836
  11. Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res. 2003;110:355–359
  12. Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):234S–264S
  13. Smith SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. [erratum appears in Circulation. 2006;113:e847] Circulation. 2006;113:2363–2372
  14. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127:531–537
  15. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias (Dimensions of methodological quality associated with estimates of treatment effects in controlled trials). [see comment] JAMA. 1995;273:408–412
  16. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. [see comment] J Neurol Sci. 1996;143:1–13
  17. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:1044–1054
  18. anonymous Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events (The SALT Collaborative Group). [see comment] Lancet. 1991;338:1345–1349
  19. Boysen G, Sorensen PS, Juhler M, et al. Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke. 1988;19:1211–1215
  20. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974;1:436–440
  21. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris (The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group). Lancet. 1992;340:1421–1425
  22. Ajani UA, Ford ES, Greenland KJ, et al. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30:74–77
  23. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69–e171
  24. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. [see comment] [erratum appears in Lancet. 2005;366:1358] Lancet. 2005;366:1267–1278
  25. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. [see comment] Lancet. 2006;368:581–588
  26. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774–782
  27. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. [see comment] JAMA. 2004;292:1555–1562
  28. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177–1184
  29. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975;72:3073–3076
  30. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. [see comment] J Am Coll Cardiol. 2005;46:986–993
  31. Pamukcu B. A review of aspirin resistance; definition, possible mechanisms, detection with platelet function tests, and its clinical outcomes. J Thromb Thrombolysis. 2007;23:213–222
  32. Gurbel PA, Bliden KP, DiChiara J, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115:3156–3164
  33. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018–2024

PII: S0002-9343(07)00985-0

doi: 10.1016/j.amjmed.2007.10.002

The American Journal of Medicine
Volume 121, Issue 1 , Pages 43-49 , January 2008

Article Tools

* Image Usage & Resolution